Early-onset enriches the identification of actionable alterations in patients with <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma.

Survival analysis showed a trend toward improved overall survival in KRAS -wt EO-PDAC patients, although the difference did not reach statistical significance (52 versus 26 months, HR 2.27, 95% CI 0.78-6.66, P = 0.13) ( Supplementary Figure S3 , available at https://doi.org/10.1016/j.esmogo.2025.100179 ).

also in 53,322 other papers